Market News
Smart Trading. Simplified.
The Common Bacteria Fighting Cancer
New breakthrough uses bacteria to "Find & Replace" cancer cells.
60 minutes calls this "the most consequential discovery in biomedicine."
A Nobel Prize winner said, "This is no longer science fiction."
Get the name of this little-known stock here >>>
Will Apple Stock Go Up After Earnings?
Investors reacted negatively to Apple’s recent Q3 2021 earnings report, taking the tech company’s shares down by around 3.5% in pre-market trading after it announced results in Q2. Apple smashed analyst estimates on both top and bottom lines in Q3, bringing in revenues of $81.4 billion and an earnings-per-share (EPS) of $1.30, topping previous Wall […]
Is this Killer new EXTRA INCOME strategy the Best Side Hustle EVER?
Have you seen this new extra-income hack yet?
Everyday Americans have been making 100%, 200%, 500%, or more... sometimes in a matter of days with this one new strategy. Some of them are retiring from their jobs because of it. Others have paid off all their debt and bought their dream homes.
You can see their stories for yourself right here.
How Do I Make $500 a Month in Dividends?
Dividend have a certain allure. Buy shares of a publicly traded company that pays a quarterly dividend, sit back, and cash the checks. The attraction of passive income is obvious. But lurking beneath the enticing quarterly dividend payout are some “gotchas” – some companies will entice investors with seemingly very attractive payouts. Why buy shares […]
Jeff Bezos' Next Big Thing
The tech visionary who built a revolutionary $1.6 trillion company from scratch is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's.
Early investors who get in by September 6th, 2021, could turn every $1,000 into $1.1 million.
Best Technology Stocks to Buy
Best Technology Stocks to Buy: Technology is forever changing. New technologies are developed every day, followed quickly by new products and services that leverage those advancements. It is an exciting course for consumers to follow, forever jumping on to the next big thing or fun new product. However, the playing field gets increasingly confusing for […]
The $62.7 Billion Memory-Saving Market
15.8 million people suffer from Alzheimer's, Parkinson's or ALS. But one little-known biotech is at the forefront revolutionizing this expected $62.7 billion market.
Invest alongside Jeff Bezos, Goldman Sachs, and BlackRock in what The Economist is calling "A Boon to Humanity."
Click here to be a part of it >>>
5 Wallets to Store Your Crypto Assets
Crypto assets grew to meteoric prominence in 2021, with about a quarter of Americans owning some form of crypto. Bitcoin’s prior spike in 2017 was still held back by lack of technical and enterprise support. But by 2020, local governments around the world were relatively savvy to crypto, and the industry flourished alongside non-fungible tokens […]
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
STAAR Surgical Buy or Sell?
STAAR Surgical Company [NASDAQ: STAA] designs, develops, manufactures and sells ophthalmic products for use in refractive, cataract, and glaucoma surgery. Operating in the ophthalmic surgical market segment, STAAR makes implantable lenses for minimally invasive ophthalmic surgical procedures. The company offers the EVO Visian implantable Collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, […]
New Investing eBook - Ultimate Guide to Real Estate Stocks.
Expand your portfolio by adding Real Estate Stocks and REITs that have outperformed the S&P 500 since the 1970s. Learn about these overlooked stocks and add high performance and stability to your portfolio.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment